Clinical trial
Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's…
NCT00056797 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00056797 |
|---|---|
| Title | Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV |
| Official title | A Randomized Controlled Study Testing the Efficacy of Immunotherapies to Control Plasma HIV RNA Concentrations Upon Interruption of Highly Active Antiretroviral Therapy (HAART). |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological, Drug |
| Interventions | ALVAC HIV vaccine (vCP1452), Interleukin-2 |
| Enrollment | 92 |
| Start date | Mar 1, 2002 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Mar 25, 2003 |
| Last update posted | Dec 14, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: